SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant market attention as traders bet on a potential short squeeze amid high short interest and heavy institutional buying. The community remains focused on upcoming regulatory catalysts, global manufacturing expansion for its cell therapy platform, and the company's long-term potential to transform oncology treatment.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility as investors weigh a strong growth narrative against persistent stock price pressure near annual lows, fueled by concerns over Alani Nu integration and competitive dynamics. The community is actively debating whether current levels represent an institutional accumulation phase ahead of upcoming earnings or reflect deeper structural headwinds in the energy drink sector.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following the successful closure of a $600 million AAA-rated asset-backed securities transaction, which has bolstered investor confidence in its AI-driven credit underwriting model. The community is currently focused on the stock's potential for a recovery, emphasizing its move toward sustained profitability and the expansion of its institutional partner network despite broader macro-economic and geopolitical headwinds.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is drawing heavy investor attention as the company aggressively pivots to value-focused menus, including new low-cost offerings and specialty drink expansions designed to combat rising operational costs and intense competition. Community sentiment is mixed, with some traders betting on a defensive rotation into the stock as a recession hedge, while others voice concerns regarding menu quality and the effectiveness of current leadership.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility driven by ongoing debates over Elevidys clinical efficacy and concerns regarding Roche's decision to initiate a new global Phase 3 trial for the therapy. While the community remains deeply polarizedwith some investors highlighting undervaluation relative to the company's approved portfolio and others raising alarms over regulatory hurdles and potential cash burnsentiment is further pressured by aggressive analyst downgrades and persistent short interest.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending as investors weigh strong underlying enterprise growth and AI-driven demand against significant short-term volatility and sector-wide sentiment shifts. The community remains divided, with many traders debating whether recent pullbacks represent an attractive entry point for a long-term AI infrastructure play or a deeper valuation reset for the software sector.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics is seeing heightened market activity driven by positive preclinical data for its ERNA-101 ovarian cancer therapy, which showed complete tumor elimination in syngeneic models. While some members of the community are optimistic about the company's valuation relative to its pipeline and MD Anderson collaboration, others remain skeptical, pointing to the company's history of reverse splits and the inherent risks of early-stage, pre-human clinical research.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is experiencing massive volume and price volatility driven by a new hedge fund report positioning the company as a key stealth supplier of optical components for AI data centers and smart glasses. The community is actively debating whether this movement signals a long-term fundamental rerating or if it represents a volatile 'buy-the-news' trap prone to rapid reversals.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is drawing intense investor attention as community members debate whether the stock is undergoing a genuine AI infrastructure re-rating or experiencing an overextended speculative bubble following strong earnings. Discussion is currently focused on the company's ambitious AGI CPU demand and the tension between its long-term growth potential and immediate concerns over supply constraints and valuation.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is currently trending due to a massive disconnect between its strong fundamentals and recent stock price volatility, with investors debating whether the stock is a 'profit machine' or vulnerable to dilution from a shelf offering. The community is sharply divided, with bulls pointing to record-breaking margins and AI-driven growth, while some bears are signaling caution regarding potential SEC investigation risks and the broader software sector's recent underperformance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and...

Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire Intel, SAP, Lunai Bioworks In Focus

U.S. stock futures were mixed on Friday following Thursday's decline, after President Donald Trump announced the extension of the ceasefire between Israel and Lebanon by three weeks. On Thursday, the...

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient...

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under...

AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up

Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD

Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures

Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.

<ul class="summary-bullets"><li>The deal would expand Lunai’s capacity to develop treatments for neurological disorders.</li><li>The transaction is executed through Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share.</li><li>The acquired technology enables compounds to remain inactive in the body until they reach the brain, where they are selectively activated.</li></ul>Lunai Bioworks, Inc. (LNAI) announced a $20 million acquisition to advance its central nervous system (CNS) drug development.&nbsp;The company will acquire blood-brain barrier (BBB) delivery technology and Alzheimer's therapeutic assets for $20 million from the Clemann Group, SAS, or its assignee, marking an expansion of Lunai’s capabilities in neurological drug research.<h2 class="st-heading-2">Transforming CNS Drug Delivery</h2>The transaction is structured as Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share, with a cap on beneficial ownership at 19.9% to remain compliant with Nasdaq regulations.&nbsp;The newly acquired delivery platform addresses one of the most persistent challenges in central nervous system (CNS) drug development, which is the effective transport of therapeutics across the blood-brain barrier.The technology ensures that compounds remain inactive in the body until reaching the brain, where they activate to target specific neurological pathways.&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks stock</a> traded over 25% higher on Thursday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Lunai’s Alzheimer’s Pipeline</h2>This acquisition directly strengthens Lunai’s Alzheimer’s program by combining validated target identification with a strong delivery method. The platform enables advanced treatments for CNS disorders where conventional drugs face penetration limitations, potentially improving both safety and effectiveness.&nbsp;<blockquote>&nbsp;"We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain.”— David Weinstein, CEO, Lunai Bioworks</blockquote>On March 19, Lunai launched the Pathfinder Consortium, a national academic-industry alliance to accelerate the development of chemical countermeasures for battlefield and terrorism threats.&nbsp;LNAI stock has declined by over 35% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-aiff-stock-surge-pre-market-today/cZ3rwPpRIjD">Why Did AIFF Stock Surge Over 20% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen

Why Did LNAI Stock Surge Over 25% Today? 

Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.

Equity

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI...

Best Manufacturing Stocks To Watch Today - March 17th

Taiwan Semiconductor Manufacturing, Applied Materials, and Lunai Bioworks are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Lunai Bioworks Inc.

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LNAI News

LNAILunai Bioworks Inc.